Research details developments in the Type-1 diabetes (juvenile diabetes) H2 2015 pipeline review market

This research provides comprehensive information on the therapeutic development for Type-1 diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

This research also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The research enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope of this research:

• The report provides a snapshot of the global therapeutic landscape of Type-1 diabetes (Juvenile Diabetes)
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Type-1 diabetes (Juvenile Diabetes) and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Type-1 diabetes (Juvenile Diabetes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Type-1 diabetes (Juvenile Diabetes) pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Complete research on H2 2015 pipeline review of Type-1 diabetes with 159 market data tables and 15 figures, spread across 639 pages is available at www.rnrmarketresearch.com/type-1-…eport.html .

Companies: 4SC AG, Adocia , AiCuris GmbH & Co. KG, Amarantus Bioscience Holdings, Inc., Ambrx, Inc., AntriaBio, Inc., Aphios Corporation, Araim Pharmaceuticals Inc., Argos Therapeutics, Inc., Artery Therapeutics, Inc, Astellas Pharma Inc., AstraZeneca Plc, Athersys, Inc., Axxam SpA, Beta-Cell NV, Biocon Limited, Biodel Inc., Biogenomics Limited, BioLineRx, Ltd., BioLingus AG, BioTherapeutics Inc., Boehringer Ingelheim GmbH, Caladrius Biosciences, Inc., Carlina Technologies SAS, Cellectis S.A., Compugen Ltd., Daewoong Pharmaceutical Co., Ltd., Dance Biopharm Inc, Diabetology (Products) Ltd, DiaMedica Inc, Diasome Pharmaceuticals, Inc., Dompe Farmaceutici S.p.A., DoNatur GmbH, Effimune SAS, Eli Lilly and Company, enGene, Inc, EpiVax, Inc., Evotec AG, F. Hoffmann-La Roche Ltd., Fate Therapeutics, Inc., Generex Biotechnology Corporation, GeNeuro SA, Gilead Sciences, Inc., GlaxoSmithKline Plc, Grifols, S.A., Halozyme Therapeutics, Inc., Hanmi Pharmaceuticals, Co.

Ltd., Heptares Therapeutics Limited, Horizon Pharma Plc, Iltoo Pharma, Innopharmax Inc., IntelliCell BioSciences Inc., Intrexon Corporation, Islet Sciences, Inc., Johnson & Johnson, Kadimastem Ltd., Kamada Ltd., Kasiak Research Private Limited, Kineta, Inc., Kissei Pharmaceutical Co., Ltd., Lexicon Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc., Lonestar Heart, Inc., MacroGenics, Inc., Medestea Research & Production S.p.A., MedImmune, LLC, Merck & Co., Inc., Merck KGaA, Meridigen Biotech Co., Ltd., Mertiva AB , MidaSol Therapeutics LP, Mitsubishi Tanabe Pharma Corporation, NatureWise Biotech & Medicals Corporation, NOD Pharmaceuticals, Inc., Novo Nordisk A/S, Noxxon Pharma AG, Omni Bio Pharmaceutical Inc., Oramed Pharmaceuticals, Inc., Orgenesis, Inc., Paras Biopharmaceuticals Finland Oy, Pathfinder Cell Therapy, Inc., Pfizer Inc., PharmaCyte Biotech, Inc., PharmaIN Corporation, Progen Pharmaceuticals Limited, Prometheon Pharma, LLC, Provid Pharmaceuticals, Inc., Purzer Pharmaceutical Co., Ltd., RedHill Biopharma Ltd., REGiMMUNE Corporation, Sanofi, SEKRIS Biomedical, Inc., Selecta Biosciences, Inc., Sevion Therapeutics, Inc., Strongbridge Biopharma plc, Therapix Biosciences Ltd, Thermalin Diabetes, LLC, Toleranzia AB, Transgene Biotek Limited, Uni-Bio Science Group Ltd., United Therapeutics Corporation, ViaCyte, Inc., Visionary Pharmaceuticals, Inc., XL-protein GmbH, XOMA Corporation and Zensun (Shanghai) Sci & Tech Co., Ltd.